New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.
Health Professionals
Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape
On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape.
Innovative Radiolabeled Antibody Shows Promise in Cancer Diagnosis and Therapy
A newly created radiolabeled antibody targeting the cancer-associated antigen IL13R?2 has demonstrated remarkable specificity in binding to cancer cells, while sparing healthy tissues. This advancement, tested across various cancer types, shows promise for enhancing tumor detection and treatment through radioimmunotherapy.
Innovative Research on Oxidizing Agents and Melanoma Cells
Melanoma, recognized as the most aggressive type of skin cancer, poses severe health risks due to its ability to metastasize, despite being less common than other skin cancers. The primary risk factor for melanoma is prolonged exposure to ultraviolet (UV) radiation, which leads to oxidative stress and inflammation in skin cells through photo-oxidative reactions.